Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31006330 | 0.95 | CCNC (0.43) | MAPTKDM4ETHRBHPGDCCNC | |
| SCHEMBL22975109 | 0.92 | USP30 (0.40) | MAPTKDM4ETHRBHPGDCCNC | |
| SCHEMBL17761437 | 0.91 | CCNC (0.47) | MAPTKDM4ETHRBHPGDCCNC | |
| SCHEMBL2020246 | 0.90 | CCNC (0.44) | MAPTKDM4ETHRBHPGDCCNC | |
| SCHEMBL1207913 | 0.88 | USP30 (0.41) | MAPTKDM4ETHRBHPGDCCNC | |
| SCHEMBL29346991 | 0.87 | USP30 (0.45) | MAPTKDM4ETHRBCCNCCDK8 | |
| SCHEMBL3496505 | 0.85 | USP30 (0.41) | MAPTKDM4ETHRBHPGDCCNC | |
| SCHEMBL2338577 | 0.85 | CCNC (0.49) | MAPTKDM4ETHRBHPGDCCNC | |
| SCHEMBL9948762 | 0.83 | USP30 (0.46) | MAPTKDM4ETHRBCCNCCDK8 | |
| SCHEMBL30801695 | 0.81 | USP30 (0.42) | MAPTKDM4ETHRBHPGDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | MAPT 2668/4885KDM4E 482/4885THRB 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.